EGFR R776C

CI-VAR-00003895Explore in graph →ENST00000275493.2:c.2326C>TCIViC 1181

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
EGFR R776C	Erlotinib	Predictive	D	Supports Sensitivity Response	—	accepted	EID4468 In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
Malignant Neoplasm1
EGFR R776C	Gefitinib	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID5818 EGFR R776C was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independence to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.